In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination

Overview

Journal Vaccines (Basel)

Date 2019 Sep 25

PMID 31546936

Citations 8

Authors

Shigetaka Shimodaira

Ryu Yanagisawa

Terutsugu Koya

Koichi Hirabayashi

Yumiko Higuchi

Takuya Sakamoto

Misa Togi

Tomohisa Kato Jr

Takashi Kobayashi

Tomonobu Koizumi

Shigeo Koido

Haruo Sugiyama

Affiliations

Soon will be listed here.

Abstract

Significant recent advances in cancer immunotherapeutics include the vaccination of cancer patients with tumor antigen-associated peptide-pulsed dendritic cells (DCs). DC vaccines with homogeneous, mature, and functional activities are required to achieve effective acquired immunity; however, the yield of autologous monocyte-derived DCs varies in each patient. Priming with a low dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF) 16-18 h prior to apheresis resulted in 50% more harvested monocytes, with a significant increase in the ratio of CD11cCD80 DCs/apheresed monocytes. The detection of antigen-specific cytotoxic T lymphocytes after Wilms' tumor 1-pulsed DC vaccination was higher in patients treated with rhG-CSF than those who were not, based on immune monitoring using tetramer analysis. Our study is the first to report that DC vaccines for cancer immunotherapy primed with low-dose rhG-CSF are expected to achieve higher acquired immunogenicity.

Citing Articles

Attitudes, expectations, and lived experiences of cancer patients receiving dendritic cell vaccine therapy in Japan.

Kitamura Y, Konya C Asia Pac J Oncol Nurs. 2023; 10(12):100317.

PMID: 38059207 PMC: 10696395. DOI: 10.1016/j.apjon.2023.100317.

Cancer Immunotherapy Using Bioengineered Micro/Nano Structured Hydrogels.

Askari E, Shokrollahi Barough M, Rahmanian M, Mojtabavi N, Sarrami Forooshani R, Seyfoori A Adv Healthc Mater. 2023; 12(27):e2301174.

PMID: 37612251 PMC: 11468077. DOI: 10.1002/adhm.202301174.

Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells.

Koya T, Yoshida K, Togi M, Niida Y, Togi S, Ura H Cancers (Basel). 2023; 15(14).

PMID: 37509288 PMC: 10377585. DOI: 10.3390/cancers15143627.

Different In Vitro-Generated MUTZ-3-Derived Dendritic Cell Types Secrete Dexosomes with Distinct Phenotypes and Antigen Presentation Potencies.

Sakamoto T, Koya T, Togi M, Yoshida K, Kato Jr T, Ishigaki Y Int J Mol Sci. 2022; 23(15).

PMID: 35955496 PMC: 9368791. DOI: 10.3390/ijms23158362.

Quality Verification with a Cluster-Controlled Manufacturing System to Generate Monocyte-Derived Dendritic Cells.

Kawaguchi H, Sakamoto T, Koya T, Togi M, Date I, Watanabe A Vaccines (Basel). 2021; 9(5).

PMID: 34065520 PMC: 8160655. DOI: 10.3390/vaccines9050533.

References

Figdor C, de Vries I, Lesterhuis W, Melief C . Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10(5):475-80. DOI: 10.1038/nm1039. View

Saito S, Yanagisawa R, Yoshikawa K, Higuchi Y, Koya T, Yoshizawa K . Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature. Cytotherapy. 2014; 17(3):330-5. DOI: 10.1016/j.jcyt.2014.10.003. View

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H . Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother. 2014; 63(8):797-806. PMC: 11028555. DOI: 10.1007/s00262-014-1554-7. View

Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y . Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. J Neurosurg. 2015; 123(4):989-97. DOI: 10.3171/2015.1.JNS141554. View

Sato K, Kawasaki H, Nagayama H, Enomoto M, Morimoto C, Tadokoro K . TGF-beta 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J Immunol. 2000; 164(5):2285-95. DOI: 10.4049/jimmunol.164.5.2285. View

Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S . Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res. 2014; 20(16):4228-39. DOI: 10.1158/1078-0432.CCR-14-0314. View

Schwartz R . Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992; 71(7):1065-8. DOI: 10.1016/s0092-8674(05)80055-8. View

Shaughnessy P, Bachier C, LeMaistre C, Akay C, Pollock B, Gazitt Y . Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors. Stem Cells. 2006; 24(7):1789-97. DOI: 10.1634/stemcells.2005-0492. View

10.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

11.

Ohsaka A, Saionji K, Kuwaki T, Takeshima T, Igari J . Granulocyte colony-stimulating factor administration modulates the surface expression of effector cell molecules on human monocytes. Br J Haematol. 1995; 89(3):465-72. DOI: 10.1111/j.1365-2141.1995.tb08350.x. View

12.

Shimodaira S, Sano K, Hirabayashi K, Koya T, Higuchi Y, Mizuno Y . Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer. Vaccines (Basel). 2015; 3(4):1004-18. PMC: 4693229. DOI: 10.3390/vaccines3041004. View

13.

Weber J, Kudchadkar R, Yu B, Gallenstein D, Horak C, Inzunza H . Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013; 31(34):4311-8. PMC: 3837092. DOI: 10.1200/JCO.2013.51.4802. View

14.

Azuma M, Cayabyab M, Buck D, Phillips J, Lanier L . Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol. 1992; 149(4):1115-23. View

15.

Leonard R, Mansi J, Keerie C, Yellowlees A, Crawford S, Benstead K . A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann Oncol. 2015; 26(12):2437-41. DOI: 10.1093/annonc/mdv389. View

16.

ONeill D, Adams S, Bhardwaj N . Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004; 104(8):2235-46. DOI: 10.1182/blood-2003-12-4392. View

17.

Aapro M, Bohlius J, Cameron D, Dal Lago L, Donnelly J, Kearney N . 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2010; 47(1):8-32. DOI: 10.1016/j.ejca.2010.10.013. View

18.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

19.

Tan P, Anasetti C, Hansen J, Melrose J, Brunvand M, Bradshaw J . Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med. 1993; 177(1):165-73. PMC: 2190874. DOI: 10.1084/jem.177.1.165. View

20.

Young J, Koulova L, Soergel S, Clark E, Steinman R, DuPont B . The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest. 1992; 90(1):229-37. PMC: 443085. DOI: 10.1172/JCI115840. View